Apatone is an investigational new drug that has recently undergone clinical trials (Phase I/II) in the United States. These clinical studies have resulted in no drug related serious adverse events. Some qualifying patients have now safely taken Apatone daily for more than five years.

Through receptors on the cell surface Apatone targets the same cells that are illuminated by Positron Emission Tomography (PET). In this way the drug selectively targets and then treats inflamed cells. The principal mechanism of action is thought to be oxidative redox modulation.

Recent research demonstrates that diseased cells often exhibit intracellular reducing environments. This is counter to the long held belief that cancer cells are oxidizing relative to normal cells. While this is true outside the cell, inside, cancer cells up-regulate anti-oxidant pathways that will protect them from the external oxidative environment they create. Consequently, cancers and many human diseases are highly sensitive to changes in redox status.

Apatone exploits this vulnerability and is the first drug of its kind aimed at this target, a redox modulation approach to disease treatment. In preclinical efficacy studies, Apatone has been shown to slow or even stop significant disease progression by aberrant cells.

Clinical studies with Apatone in cancer, non-cancerous neoplastic diseases and inflammatory disease suggest this pharmacologic approach offers much promise to safely, effectively and affordably improve treatment protocols over a wide range of diseases.

IC-MedTech has received FDA orphan drug designation in five indications in the US and is awaiting orphan designation for two indications in Europe. IC-MedTech is continuing to advance this first in class therapy toward regulatory approval through collaboration and partnerships.

Read more about the research here – Summa’s “Exploring Apatone”